|
Match
|
Document |
Document Title |
|
|
US20140023707 |
Co-Processed Carbohydrate System as a Quick-Dissolve Matrix for Solid Dosage Forms
The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly... |
|
|
US20130243856 |
ORAL DRUG DELIVERY SYSTEM
An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active... |
|
|
US20150182467 |
TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS
Methods of decreasing abuse potentials of oral opioid dosage forms are described. In the methods, an opioid antagonist in a substantially non-releasable form is included in oral dosage forms... |
|
|
US20110268797 |
MULTICOATED ALISKIREN FORMULATIONS
An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers. |
|
|
US20110076326 |
MODIFIED PROTEIN EXCIPIENT FOR DELAYED-RELEASE TABLET
The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as... |
|
|
US20130095177 |
METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD
The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form... |
|
|
US20130059004 |
ORAL DRUG DELIVERY SYSTEM
An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active... |
|
|
US20110045068 |
PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI
The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI. |
|
|
US20140023705 |
DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The... |
|
|
US20140079780 |
Crush resistant delayed-release dosage forms
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20110117193 |
ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS
The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as... |
|
|
US20140314846 |
MULTIPLE UNIT PHARMACEUTICAL FORMULATION
An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an... |
|
|
US20100297226 |
MULTIPLE UNIT PHARMACEUTICAL FORMULATION
An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an... |
|
|
US20150056277 |
DRUG DELIVERY SYSTEM
The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally... |
|
|
US20150216992 |
EXTENDED RELEASE COMPOSITIONS OF AN AMINOALKYL NITRATE
The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed... |
|
|
US20140010874 |
Tamper Resistant Solid Oral Dosage Forms
Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. |
|
|
US20120251623 |
METHOD OF ADMINISTERING AN ACTIVE INGREDIENT USING A CHEWABLE ORAL DOSAGE FROM COMPRISING TEXTURE MASKED PARTICLES
In one aspect, the present invention features a method of administering an active ingredient, said method comprising chewing an oral dosage form comprising a texture masked particle, said texture... |
|
|
US20150196494 |
STABILIZED PICOPLATIN ORAL DOSAGE FORM
The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active, metal salts. The core of the tablet is a... |
|
|
US20100255091 |
ORAL FAST DISINTEGRATING TABLETS
The present invention refers to an orally fast disintegrable pharmaceutically acceptable multiple units tablet dosage form comprising a) tablet excipients comprising a disintegrant and b)... |
|
|
US20120189693 |
ORAL DOSAGE FORMS
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0... |
|
|
US20130273157 |
ORALLY DISINTEGRATING TABLET
A orally disintegrating tablet is obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules... |
|
|
US20150140085 |
FORMULATIONS COMPRISING IBRUTINIB
Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for... |
|
|
US20130022678 |
ORAL CONTROLLED RELEASE DOSAGE FORM
A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. |
|
|
US20110268799 |
ORAL CONTROLLED RELEASE DOSAGE FORM
A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. |
|
|
US20130259936 |
LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME
The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. |
|
|
US20140287042 |
Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases
The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active... |
|
|
US20130122090 |
Multiple Unit Tablet Composition
A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than... |
|
|
US20140242160 |
CALCIUM SUPPLEMENT
An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream... |
|
|
US20100330176 |
Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and... |
|
|
US20150250742 |
Dosage Forms Containing Terbutaline Sulphate
A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising... |
|
|
US20110274751 |
TRIMETAZIDINE FORMULATION WITH DIFFERENT RELEASE PROFILES
A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled... |
|
|
US20140170216 |
BUPROPION HYDROBROMIDE POLYMORPHS
Polymorphous and amorphous forms of bupropion hydrobromide are described. |
|
|
US20130059005 |
BUPROPION HYDROBROMIDE POLYMORPHS
Polymorphous and amorphous forms of bupropion hydrobromide are described. |
|
|
US20150118303 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual... |
|
|
US20150118302 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual... |
|
|
US20140287039 |
Abiraterone Acetate Formulation
Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequestering agent as well as methods for producing... |
|
|
US20140170215 |
ORALLY DISINTEGRATING TABLETS AND METHODS OF MANUFACTURE
A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture... |
|
|
US20140212488 |
ORAL TABLET FORMULATION CONSISTING OF IMMEDIATE RELEASE ROSUVASTATIN AND EXTENDED RELEASE METFORMIN
A solid dosage product and formulation containing a fixed combination of rosuvastatin and metformin is provided here. In the formulation rosuvastatin is delivered immediately to the patient and... |
|
|
US20130202698 |
L-ORNIDAZOLE FORMULATIONS AND THEIR APPLICATIONS IN TREATMENT OF PARASITIC INFECTIONS
This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular... |
|
|
US20130273156 |
ORAL PHARMACEUTICAL TABLET FOR CONTROLLED RELEASE OF MESALAZINE AND PROCESS FOR OBTAINING IT
The invention provides an oral pharmaceutical tablet for controlled release of mesalazine or a pharmaceutically acceptable salt thereof as active ingredient with a core and a gastro-resistant... |
|
|
US20110104272 |
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE
Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of... |
|
|
US20120064159 |
Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
Multilayer tablets of a non-steroidal anti-inflammatory drug (NSAID) and/or acetaminophen for oral administration containing an immediate release layer or layers containing a NSAID and/or... |
|
|
US20110091546 |
COMPOSITION FOR RAPID DISINTEGRATING TABLET IN ORAL CAVITY
The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid... |
|
|
US20120294938 |
PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION
Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active... |
|
|
US20140302137 |
FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES
The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. |
|
|
US20120009259 |
FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES
The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. |
|
|
US20150056275 |
CONTROLLED-RELEASE SOLID DOSAGE FORMS OF MESALAMINE
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of... |
|
|
US20130344146 |
DRY FORMULATIONS OF ARIPIPRAZOLE
The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition. |
|
|
US20140322321 |
TABLET CAPABLE OF COMBATTING MISUSE BY INJECTION
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible... |
|
|
US20150037407 |
METHOD TO IMPROVE THE SAFETY OF HANDLING OF HIGH POTENCY DRUGS IN SOLID DOSAGE FORMS WITHOUT CHANGING THEIR EFFICACY
A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy... |